R-Pharm plans to make Russia a hub for production of COVID-19 vaccines

1 September 2020

R-Pharm, one of Russia’s leading drugmakers that is owned by a well-known businessman Alexey Repik, plans to make Russia one of the world’s hubs for the production and exports of COVID-19 vaccines within the next several years, according to recent statements by the company and some Russian media reports.

As part of these plans, the company is ready to begin exports of its vaccine to more than 30 markets throughout the world, paying particular attention for supplies to the Middle East region, the Balkan states and CIS countries.

So far, R-Pharm has announced its plans to launch the production of at least two vaccines at its facilities, which may take place already this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK